UroGen Pharma Ltd. (NASDAQ:URGN) Position Reduced by Schonfeld Strategic Advisors LLC

Schonfeld Strategic Advisors LLC reduced its stake in shares of UroGen Pharma Ltd. (NASDAQ:URGN) by 45.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 68,100 shares of the company’s stock after selling 56,200 shares during the period. Schonfeld Strategic Advisors LLC owned about 0.29% of UroGen Pharma worth $725,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Rhumbline Advisers increased its holdings in UroGen Pharma by 2.8% in the fourth quarter. Rhumbline Advisers now owns 51,270 shares of the company’s stock valued at $546,000 after buying an additional 1,402 shares during the last quarter. MetLife Investment Management LLC increased its holdings in shares of UroGen Pharma by 13.6% in the 4th quarter. MetLife Investment Management LLC now owns 22,766 shares of the company’s stock valued at $242,000 after acquiring an additional 2,727 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of UroGen Pharma by 3.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 93,517 shares of the company’s stock valued at $996,000 after acquiring an additional 3,024 shares in the last quarter. Legal & General Group Plc lifted its stake in UroGen Pharma by 24.6% during the fourth quarter. Legal & General Group Plc now owns 19,845 shares of the company’s stock worth $211,000 after purchasing an additional 3,920 shares during the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new position in UroGen Pharma in the fourth quarter worth $59,000. Institutional investors and hedge funds own 91.29% of the company’s stock.

UroGen Pharma Trading Down 3.0 %

NASDAQ:URGN opened at $10.35 on Friday. The stock has a market cap of $477.21 million, a price-to-earnings ratio of -3.29 and a beta of 0.66. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00. UroGen Pharma Ltd. has a 1 year low of $8.94 and a 1 year high of $20.70. The business has a fifty day moving average of $10.64 and a 200-day moving average of $10.99.

UroGen Pharma (NASDAQ:URGN) last released its earnings results on Monday, March 10th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.11). The business had revenue of $24.57 million for the quarter, compared to analysts’ expectations of $25.25 million. Equities analysts predict that UroGen Pharma Ltd. will post -3.12 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on URGN. Scotiabank started coverage on shares of UroGen Pharma in a report on Wednesday, April 16th. They set a “sector outperform” rating and a $23.00 target price on the stock. Guggenheim reissued a “buy” rating on shares of UroGen Pharma in a report on Tuesday, April 29th. The Goldman Sachs Group lowered their target price on UroGen Pharma from $22.00 to $16.00 and set a “neutral” rating for the company in a report on Thursday, April 17th. LADENBURG THALM/SH SH assumed coverage on UroGen Pharma in a report on Wednesday, February 19th. They issued a “buy” rating and a $31.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and set a $55.00 price objective on shares of UroGen Pharma in a research note on Monday, April 28th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $32.86.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.